211 related articles for article (PubMed ID: 32227023)
1. Nanoengineered immunosuppressive therapeutics modulating M1/M2 macrophages into the balanced status for enhanced idiopathic pulmonary fibrosis therapy.
Chang X; Xing L; Wang Y; Zhou TJ; Shen LJ; Jiang HL
Nanoscale; 2020 Apr; 12(16):8664-8678. PubMed ID: 32227023
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus alleviates pulmonary fibrosis progression through inhibiting the activation and interaction of ILC2 and monocytes.
Liu B; Jiang Q; Chen R; Zhang H; Xia Q; Shao C; Liu X; Wang M; Shi Y; Zhu J; Zhao R; Jiang H; Gao S; Li X; Zhou H; Yang C; Huang H
Int Immunopharmacol; 2024 May; 132():111999. PubMed ID: 38581994
[TBL] [Abstract][Full Text] [Related]
3. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
4. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
5. Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis.
Pan T; Zhou Q; Miao K; Zhang L; Wu G; Yu J; Xu Y; Xiong W; Li Y; Wang Y
Theranostics; 2021; 11(3):1192-1206. PubMed ID: 33391530
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
7. Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206
Wang J; Xu L; Xiang Z; Ren Y; Zheng X; Zhao Q; Zhou Q; Zhou Y; Xu L; Wang Y
Cell Death Dis; 2020 Feb; 11(2):136. PubMed ID: 32075954
[TBL] [Abstract][Full Text] [Related]
8. Inflammation and immunity in IPF pathogenesis and treatment.
Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M
Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705
[TBL] [Abstract][Full Text] [Related]
9. M2 macrophages promote myofibroblast differentiation of LR-MSCs and are associated with pulmonary fibrogenesis.
Hou J; Shi J; Chen L; Lv Z; Chen X; Cao H; Xiang Z; Han X
Cell Commun Signal; 2018 Nov; 16(1):89. PubMed ID: 30470231
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.
Craig VJ; Zhang L; Hagood JS; Owen CA
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):585-600. PubMed ID: 26121236
[TBL] [Abstract][Full Text] [Related]
11. Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization.
Yan L; Hou C; Liu J; Wang Y; Zeng C; Yu J; Zhou T; Zhou Q; Duan S; Xiong W
Sci China Life Sci; 2023 Nov; 66(11):2571-2586. PubMed ID: 37340175
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus ameliorates bleomycin-induced pulmonary fibrosis by inhibiting M2 macrophage polarization via JAK2/STAT3 signaling.
Liu B; Jiang Q; Chen R; Gao S; Xia Q; Zhu J; Zhang F; Shao C; Liu X; Li X; Zhou H; Yang C; Huang H
Int Immunopharmacol; 2022 Dec; 113(Pt A):109424. PubMed ID: 36461589
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-Targeted Lung Delivery of Dexamethasone Improves Pulmonary Fibrosis Therapy via Regulating the Immune Microenvironment.
Sang X; Wang Y; Xue Z; Qi D; Fan G; Tian F; Zhu Y; Yang J
Front Immunol; 2021; 12():613907. PubMed ID: 33679754
[TBL] [Abstract][Full Text] [Related]
14. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis.
Herrmann FE; Wollin L; Wirth J; Gantner F; Lämmle B; Wex E
Br J Pharmacol; 2017 Nov; 174(21):3848-3864. PubMed ID: 28810065
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung disease.
Isshiki T; Vierhout M; Naiel S; Ali P; Yazdanshenas P; Kumaran V; Yang Z; Dvorkin-Gheva A; Rullo AF; Kolb MRJ; Ask K
Biochem Pharmacol; 2023 May; 211():115501. PubMed ID: 36921632
[TBL] [Abstract][Full Text] [Related]
16. Magnetic liposome as a dual-targeting delivery system for idiopathic pulmonary fibrosis treatment.
Wang X; Wang Y; Xue Z; Wan W; Li Y; Qin H; Zhu Y; Tian F; Yang J
J Colloid Interface Sci; 2023 Apr; 636():388-400. PubMed ID: 36640550
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
19. TREM2 Insufficiency Protects against Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization.
Luo Q; Deng D; Li Y; Shi H; Zhao J; Qian Q; Wang W; Cai J; Yu W; Liu J
Int Immunopharmacol; 2023 May; 118():110070. PubMed ID: 37003186
[TBL] [Abstract][Full Text] [Related]
20. Multi-Modal Characterization of Monocytes in Idiopathic Pulmonary Fibrosis Reveals a Primed Type I Interferon Immune Phenotype.
Fraser E; Denney L; Antanaviciute A; Blirando K; Vuppusetty C; Zheng Y; Repapi E; Iotchkova V; Taylor S; Ashley N; St Noble V; Benamore R; Hoyles R; Clelland C; Rastrick JMD; Hardman CS; Alham NK; Rigby RE; Simmons A; Rehwinkel J; Ho LP
Front Immunol; 2021; 12():623430. PubMed ID: 33746960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
